Open an account

Shattuck Labs

STTK · NASDAQ

$5.84+$0.47 (+8.75%)TodayMarket closed ·
Prev close $5.37

About STTK

Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 40 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Employees
40
Headquarters
Austin, Texas
Listed
Oct 9, 2020
Sector
Health Care
Industry
Biotechnology
Website
shattucklabs.com

STTK key statistics

Market cap
586.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.40M
Volume
1.56M
Open price
$5.39
High today
$5.87
Low today
$5.31
52 Week high
$8.33
52 Week low
$1.72

Shattuck Labs (STTK) at a glance

As of Oct 20, 2026, Shattuck Labs (STTK) shares are priced at $5.84, giving the company a market cap of 586.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.31 and $5.87. The current price is 10.0% above the day's low and 0.5% below its high.

Volume so far is 1.56M shares, in line with the average of 1.40M shares a day.

Over the past year Shattuck Labs has ranged from $1.72 to $8.33, and now sits 62% of the way up that range.

Shattuck Labs met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.12 per share against an estimate of -$0.1197.

STTK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 10.3% on average.

  1. Q3 FY24: reported -$0.33 per share against an estimate of -$0.4251
  2. Q4 FY24: reported -$0.37 per share against an estimate of -$0.3258
  3. Q1 FY25: reported -$0.27 per share against an estimate of -$0.2869
  4. Q2 FY25: reported -$0.24 per share against an estimate of -$0.2499
  5. Q3 FY25: reported -$0.14 per share against an estimate of -$0.1516
  6. Q4 FY25: reported -$0.12 per share against an estimate of -$0.1394
  7. Q1 FY26: reported -$0.13 per share against an estimate of -$0.1409
  8. Q2 FY26: reported -$0.12 per share against an estimate of -$0.1197

STTK news

  • Vandana Singh

    Why Is Shattuck Labs Stock Trading Lower On Monday?

  • Avi Kapoor

    Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Dow Surges Over 100 Points; Pfizer Earnings Top Views

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseGlobe Newswire

    Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

  • Avi Kapoor

    Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Similar companies

Companies in the same industry as Shattuck Labs

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.